Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 15;9(3):3353-3364.
doi: 10.18632/oncotarget.23261. eCollection 2018 Jan 9.

Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders

Shuhua Yi  1 , Zengjun Li  1 , Dehui Zou  1 , Wenjie Xiong  1 , Heng Li  1 , Rui Cui  1   2 , Chengwen Li  1 , Yuting Yan  1 , Wei Liu  1 , Rui Lv  1 , Zhen Yu  1 , Weiwei Chen  1 , Yan Xu  1 , Gang An  1 , Huijun Wang  1 , Kun Ru  1 , Tao Cheng  1 , Jianxiang Wang  1 , Lugui Qiu  1
Affiliations

Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders

Shuhua Yi et al. Oncotarget. .

Abstract

B-cell chronic lymphoproliferative disorders (B-CLPD) comprise several entities with indolent clinical manifestations but heterogeneous survival. Cytogenetic aberrations are now the standard prognostic predictors in chronic lymphocytic leukemia (CLL) but have been less investigated in other subtypes of B-CLPD. In this study, we detected cytogenetic aberrations by fluorescence in situ hybridization (FISH) in 875 B-CLPD patients, based on a panel probes locating at 13q14, 11q22, 17p13 and CEP12. We identified del17p acted as the independent adverse cytogenetic predictor for overall survival (OS) in CLL. Del13q, del11q and del17p were adverse factors for OS in Waldenström's macroglobulinemia in the univariate analysis but lost their role in the multivariate analysis. Trisomy 12 acted as an independent poor factor for both marginal zone lymphoma (MZL) and unclassified B-CLPD (BCLPD-U) subtype. Del17p did not impact survival in MZL and BCLPD-U patients. These contrasting results indicate different roles of the same cytogenetic aberrations in the pathogenesis of each B-CLPD subtype. As del17p contributed to the poorest survival in CLL and desired extraordinary treatment strategy, the imitation of CLL strategy to other B-CLPD with del17p should be carefully advocated based on this study.

Keywords: B-cell chronic lymphoproliferative disorders; chronic lymphocytic leukemia; cytogenetic aberration; del 17p; prognosis.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
The prognostic role of del17p in patients with different B-CLPD subtypes: CLL (A), WM (B), MZL (C) or BCLPD-U (D).
Figure 2
Figure 2. Patients with del13q in WM had poor overall survival
Figure 3
Figure 3. Survival curves of trisomy 12
Patients with trisomy 12 had adverse overall survival in MZL (A) and BCLPD-U group (B).
Figure 4
Figure 4. Survival comparisons of patients with del17p in different B-CLPD subtypes
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th edn. IARC Press; Lyon: 2008. pp. 194–5.
    1. Morice WG, Kurtin PJ, Hodnefield JM, Shanafelt TD, Hoyer JD, Remstein ED, Hanson CA. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc. 2008;83:776–85. https://doi.org/10.4065/83.7.776S0025-6196(11)60916-6. - DOI - PubMed
    1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6. https://doi.org/MJBA-432602. - PubMed
    1. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007;21:2442–51. https://doi.org/10.1038/sj.leu.2404935. - DOI - PubMed
    1. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–74. https://doi.org/10.1016/S0140-6736(10)61381-5. - DOI - PubMed